Jubilant Ingrevia Limited , a leading global integrated Life Sciences & Specialty Chemicals company, has announced its financial results for the first quarter of fiscal year 2026, ending June 30, 2025. The company reported robust growth in both revenue and profitability, alongside significant corporate developments.

Financial Highlights

For Q1 FY26, Jubilant Ingrevia reported:

• Consolidated revenue from operations of ₹1,037.95 crore, up 1.3% year-over-year
• EBITDA of ₹153.00 crore, showing a substantial increase of 29% compared to Q1 FY25
• Net profit of ₹75.10 crore, marking an impressive 54% growth year-over-year
• Earnings per share (EPS) of ₹4.75, up from ₹3.08 in the same quarter last year

The company's performance was driven by strong growth in its Specialty Chemicals segment and improved profitability across business units.

Segment Performance

The Specialty Chemicals segment continued to be the star performer, contributing 46% to the total revenue and 76% to the overall EBITDA.

Corporate Developments

In addition to the financial results, Jubilant Ingrevia announced several key corporate developments:

1. Board Changes: The company appointed Ms. Aashti Bhartia as an Additional Non-Executive Director, effective August 1, 2025. Concurrently, Mr. Arjun Shanker Bhartia resigned from his position as Non-Executive Director.

2. Stock Options: The Board approved the grant of 47,033 stock options to eligible employees under the Jubilant Ingrevia Employees Stock Option Plan 2021.

3. Investment in Renewable Energy: During the quarter, Jubilant Ingrevia made its third tranche of investment in O2 Renewable Energy XVIII Private Limited, which has now become an associate of the company. This move aligns with the company's strategy to access renewable energy and meet its increasing power demands through green energy sources.

Management Commentary

Mr. Shyam S Bhartia, Chairman, and Mr. Hari S Bhartia, Co-Chairman of Jubilant Ingrevia Limited, commented on the results: "We are pleased with our performance in Q1 FY26. Our specialty chemical businesses have continued to perform strongly, growing double digits year-over-year. Ongoing cost optimization initiatives have further enhanced profitability, with EBITDA rising by 29% and Profit After Tax increasing by an impressive 54% year-over-year."

They added, "For FY26, we anticipate continued growth and improved performance, driven by advancements in our Specialty Chemicals and Nutrition businesses, and expected recovery in the Acetyls portfolio. We remain committed to our Lean 2.0 cost efficiency initiatives and are on track to deliver the big CDMO order in early 2026, which should further accelerate our growth trajectory in coming quarters."

Mr. Deepak Jain, CEO & Managing Director, highlighted the progress of the company's PINNACLE strategy: "The financial results for Q1 FY26 reflect our Pinnacle strategy, with continued growth momentum driven by the Specialty & Nutrition segment. Our CDMO business is seeing significant expansion in its opportunity pipeline, particularly in the pharmaceutical segment."

With a strong start to the fiscal year and strategic initiatives in place, Jubilant Ingrevia appears well-positioned for sustained growth and value creation in the coming quarters.

Jubilant Ingrevia Limited , a leading integrated life sciences and specialty chemicals company, has reported a robust financial performance for the first quarter, along with significant changes to its board composition.

Financial Highlights

The company's standalone net profit for Q1 soared by 54% year-over-year to Rs 75.00 crore, compared to Rs 49.00 crore in the same quarter last year. This impressive growth was achieved despite a modest 1% increase in total revenue from operations, which stood at Rs 1,038.00 crore for the quarter.

Jubilant Ingrevia's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) for Q1 rose by 29% year-on-year to Rs 153.00 crore, with the EBITDA margin improving to 15% from 12% in the corresponding quarter of the previous year.

Segment Performance

The company's Specialty Chemicals segment continued to be the star performer, contributing 46% to the overall revenue and a significant 76% to the EBITDA. This segment witnessed an 11% year-on-year growth in revenue, reaching Rs 478.00 crore for the quarter.

The Chemical Intermediates segment, while experiencing a 7% year-on-year decline in revenue to Rs 381.00 crore, showed signs of recovery with a 2% quarter-on-quarter growth. The Nutrition & Health Solutions segment reported a slight 4% year-on-year decrease in revenue to Rs 179.00 crore.

Board Changes and Corporate Developments

In a significant move, the company announced the appointment of Ms. Aashti Bhartia as an Additional Non-Executive Director, effective August 1, 2025. Ms. Bhartia brings over 15 years of experience in corporate governance and strategic leadership to the board.

Simultaneously, Mr. Arjun Shanker Bhartia has stepped down from his position as Non-Executive Director, citing personal reasons.

The company also disclosed its investment in renewable energy, having made a third tranche investment in 02 Renewable Energy XVIII Private Limited. This strategic move aims to fulfill Jubilant Ingrevia's power requirements through green energy sources.

Management Commentary

Mr. Shyam S Bhartia, Chairman, and Mr. Hari S Bhartia, Co-Chairman of Jubilant Ingrevia Limited, expressed satisfaction with the quarter's performance, stating, "Our specialty chemical businesses have continued to perform strongly, growing double digit YoY and with stable performance on QoQ basis. Our Chemical Intermediates business has started to recover marginally with QoQ growth."

They also highlighted the positive impact of ongoing cost optimization initiatives on profitability and expressed optimism about the company's future outlook, particularly in light of the anticipated delivery of a significant CDMO order in early 2026.

Future Outlook

Looking ahead, the management anticipates continued growth and improved performance, driven by advancements in the Specialty Chemicals and Nutrition businesses, and an expected recovery in the Acetyls portfolio. The company remains committed to its Lean 2.0 cost efficiency initiatives and is on track to deliver a major CDMO order in early 2026, which is expected to further accelerate its growth trajectory.

Jubilant Ingrevia's strong Q1 performance, coupled with strategic investments and board changes, positions the company well for sustained growth in the evolving global chemicals sector.